These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 39292321)

  • 1. Advances in targeting cancer epigenetics using CRISPR-dCas9 technology: A comprehensive review and future prospects.
    Rajanathadurai J; Perumal E; Sindya J
    Funct Integr Genomics; 2024 Sep; 24(5):164. PubMed ID: 39292321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting cancer epigenetics with CRISPR-dCAS9: Principles and prospects.
    Rahman MM; Tollefsbol TO
    Methods; 2021 Mar; 187():77-91. PubMed ID: 32315755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol for Delivery of CRISPR/dCas9 Systems for Epigenetic Editing into Solid Tumors Using Lipid Nanoparticles Encapsulating RNA.
    Woodward EA; Wang E; Wallis C; Sharma R; Tie AWJ; Murthy N; Blancafort P
    Methods Mol Biol; 2024; 2842():267-287. PubMed ID: 39012601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generation of Cell Lines Stably Expressing a dCas9-Fusion or sgRNA to Address Dynamics of Long-Term Effects of Epigenetic Editing.
    Sarno F; Koncz M; Eilers RE; Verschure PJ; Rots MG
    Methods Mol Biol; 2024; 2842():289-307. PubMed ID: 39012602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. dCas9 Tells Tales: Probing Gene Function and Transcription Regulation in Cancer.
    Mohamad Zamberi NN; Abuhamad AY; Low TY; Mohtar MA; Syafruddin SE
    CRISPR J; 2024 Apr; 7(2):73-87. PubMed ID: 38635328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishment of Cell Lines Stably Expressing dCas9-Fusions to Address Kinetics of Epigenetic Editing.
    Goubert D; Koncz M; Kiss A; Rots MG
    Methods Mol Biol; 2018; 1767():395-415. PubMed ID: 29524148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-based epigenome editing: mechanisms and applications.
    Fadul SM; Arshad A; Mehmood R
    Epigenomics; 2023 Nov; 15(21):1137-1155. PubMed ID: 37990877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR/Cas mediated epigenome editing for cancer therapy.
    Ansari I; Chaturvedi A; Chitkara D; Singh S
    Semin Cancer Biol; 2022 Aug; 83():570-583. PubMed ID: 33421620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review on CRISPR/Cas-based epigenetic regulation in plants.
    Jogam P; Sandhya D; Alok A; Peddaboina V; Allini VR; Zhang B
    Int J Biol Macromol; 2022 Oct; 219():1261-1271. PubMed ID: 36057300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9 in Genome Editing and Beyond.
    Wang H; La Russa M; Qi LS
    Annu Rev Biochem; 2016 Jun; 85():227-64. PubMed ID: 27145843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/dCas9 platforms in plants: strategies and applications beyond genome editing.
    Moradpour M; Abdulah SNA
    Plant Biotechnol J; 2020 Jan; 18(1):32-44. PubMed ID: 31392820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRISPR/Cas9 in epigenetics studies of health and disease.
    Sar P; Dalai S
    Prog Mol Biol Transl Sci; 2021; 181():309-343. PubMed ID: 34127198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repurposing CRISPR System for Transcriptional Activation.
    Chen M; Qi LS
    Adv Exp Med Biol; 2017; 983():147-157. PubMed ID: 28639197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Modification of Epigenetic Marks Using CRISPR/dCas9-SunTag-Based Modular Epigenetic Toolkit.
    Song MK; Kim YS
    Methods Mol Biol; 2024; 2761():81-91. PubMed ID: 38427231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CRISPR/Cas9-Mediated Genome Editing of Epigenetic Factors for Cancer Therapy.
    Yao S; He Z; Chen C
    Hum Gene Ther; 2015 Jul; 26(7):463-71. PubMed ID: 26075804
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances of epigenetic editing.
    Gjaltema RAF; Rots MG
    Curr Opin Chem Biol; 2020 Aug; 57():75-81. PubMed ID: 32619853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-mediated modification of DNA methylation pattern in the new era of cancer therapy.
    Maroufi F; Maali A; Abdollahpour-Alitappeh M; Ahmadi MH; Azad M
    Epigenomics; 2020 Oct; 12(20):1845-1859. PubMed ID: 33185489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inducible CRISPR-dCas9 Transcriptional Systems for Sensing and Genome Regulation.
    Wu H; Wang F; Jiang JH
    Chembiochem; 2021 Jun; 22(11):1894-1900. PubMed ID: 33433941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenome editing for targeted DNA (de)methylation: a new perspective in modulating gene expression.
    Seem K; Kaur S; Kumar S; Mohapatra T
    Crit Rev Biochem Mol Biol; 2024; 59(1-2):69-98. PubMed ID: 38440883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Harnessing the Potential of CRISPR/Cas in Atherosclerosis: Disease Modeling and Therapeutic Applications.
    Siew WS; Tang YQ; Kong CK; Goh BH; Zacchigna S; Dua K; Chellappan DK; Duangjai A; Saokaew S; Phisalprapa P; Yap WH
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.